Breakthrough in cervical cancer treatment
Image credit: nci via Unsplash
Recent clinical trial results published in The Lancet journal highlight a significant breakthrough in cervical cancer treatment. The study demonstrates that a new therapeutic approach, which involves administering chemotherapy prior to chemoradiotherapy for locally advanced cervical cancer, significantly reduces the risk of death from the disease by 40%. This approach not only represents a clinically meaningful improvement but is also cost-effective, marking the most significant advancement in cervical cancer treatment outcomes in over two decades.
Source
McCormack, M., Eminowicz, G., Gallardo, D., Diez, P., Farrelly, L., Kent, C., Hudson, E., Panades, M., Mathew, T., Anand, A., Persic, M., Forrest, J., Bhana, R., Reed, N., Drake, A., Adusumalli, M., Mukhopadhyay, A., King, M., Whitmarsh, K., McGrane, J., … INTERLACE investigators (2024). Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial. Lancet (London, England), 404(10462), 1525–1535. https://doi.org/10.1016/S0140-6736(24)01438-7
Additional Reading
https://www.cnn.com/2024/10/16/health/cervical-cancer-treatment-trial/index.html
https://www.theguardian.com/society/2024/oct/14/new-cervical-cancer-treatment-regime-cuts-risk-dying
https://www.healthline.com/health-news/cervical-cancer-treatment-lowers-death-risk